| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.43▼ | 1.43▼ | 1.43▼ | 1.40▼ | 1.43▼ |
| MA10 | 1.42▲ | 1.41▲ | 1.41▲ | 1.42▼ | 1.45▼ |
| MA20 | 1.40▲ | 1.41▲ | 1.41▲ | 1.44▼ | 1.54▼ |
| MA50 | 1.43▼ | 1.45▼ | 1.45▼ | 1.45▼ | 1.35▲ |
| MA100 | 1.44▼ | 1.50▼ | 1.51▼ | 1.55▼ | 2.07▼ |
| MA200 | 1.53▼ | 1.49▼ | 1.45▼ | 1.32▲ | 2.83▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.006▲ | 0.006▲ | -0.006▼ | -0.014▼ |
| RSI | 50.647▲ | 48.645▼ | 48.375▼ | 44.110▼ | 48.510▼ |
| STOCH | 82.677▲ | 84.361▲ | 84.361▲ | 21.123 | 47.849 |
| WILL %R | -42.857 | -37.500 | -37.500 | -86.957▼ | -62.903 |
| CCI | 32.353 | 50.964 | 50.964 | -46.678 | -28.260 |
|
Saturday, May 23, 2026 04:21 PM
Merck (NYSE:MRK) reported positive Phase 3 results for its antibody drug conjugate sacituzumab tirumotecan in advanced endometrial cancer and in lung cancer combinations. The company said sacituzumab ...
|
|
Saturday, May 23, 2026 06:36 AM
Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met ...
|
|
Tuesday, May 05, 2026 05:17 PM
Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/05/26 | 1.40 | 1.4694 | 1.40 | 1.40 | 63,212 |
| 21/05/26 | 1.38 | 1.4401 | 1.38 | 1.43 | 60,597 |
| 20/05/26 | 1.40 | 1.4279 | 1.39 | 1.41 | 82,625 |
| 19/05/26 | 1.40 | 1.42 | 1.37 | 1.39 | 53,798 |
| 18/05/26 | 1.42 | 1.44 | 1.39 | 1.39 | 36,849 |
| 15/05/26 | 1.45 | 1.45 | 1.41 | 1.42 | 19,552 |
| 14/05/26 | 1.43 | 1.475 | 1.425 | 1.46 | 51,605 |
| 13/05/26 | 1.44 | 1.46 | 1.40 | 1.43 | 52,747 |
| 12/05/26 | 1.45 | 1.49 | 1.43 | 1.44 | 47,719 |
| 11/05/26 | 1.47 | 1.50 | 1.43 | 1.45 | 63,873 |
|
|
||||
|
|
||||
|
|